Schultz Taylor I, Raucci Frank J, Salloum Fadi N
Department of Physiology and Biophysics, Virginia Commonwealth University, Richmond, Virginia, USA.
Department of Pediatric Cardiology, Children's Hospital of Richmond at Virginia Commonwealth University Hospital System, Richmond, Virginia, USA.
JACC Basic Transl Sci. 2022 Mar 9;7(6):608-625. doi: 10.1016/j.jacbts.2021.11.004. eCollection 2022 Jun.
Duchenne muscular dystrophy (DMD) is a devastating disease affecting approximately 1 in every 3,500 male births worldwide. Multiple mutations in the dystrophin gene have been implicated as underlying causes of DMD. However, there remains no cure for patients with DMD, and cardiomyopathy has become the most common cause of death in the affected population. Extensive research is under way investigating molecular mechanisms that highlight potential therapeutic targets for the development of pharmacotherapy for DMD cardiomyopathy. In this paper, the authors perform a literature review reporting on recent ongoing efforts to identify novel therapeutic strategies to reduce, prevent, or reverse progression of cardiac dysfunction in DMD.
杜氏肌营养不良症(DMD)是一种严重的疾病,全球每3500例男性新生儿中约有1例受其影响。肌营养不良蛋白基因的多种突变被认为是DMD的根本原因。然而,DMD患者仍然无法治愈,心肌病已成为受影响人群中最常见的死亡原因。目前正在进行广泛的研究,以探究分子机制,这些机制突出了DMD心肌病药物治疗开发的潜在治疗靶点。在本文中,作者进行了一项文献综述,报告了最近为确定减少、预防或逆转DMD心脏功能障碍进展的新治疗策略所做的努力。